Cellebrite DI Ltd (CLBT) concluded trading on Thursday at a closing price of $21.70, with 3.82 million shares of worth about $82.8 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 57.25% during that period and on February 13, 2025 the price saw a loss of about -12.92%. Currently the company’s common shares owned by public are about 208.08M shares, out of which, 83.43M shares are available for trading.
Stock saw a price change of -13.92% in past 5 days and over the past one month there was a price change of -2.60%. Year-to-date (YTD), CLBT shares are showing a performance of -1.50% which increased to 133.84% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $8.91 but also hit the highest price of $26.30 during that period. The average intraday trading volume for Cellebrite DI Ltd shares is 1.53 million. The stock is currently trading -9.98% below its 20-day simple moving average (SMA20), while that difference is down -3.36% for SMA50 and it goes to 29.54% higher than SMA200.
Cellebrite DI Ltd (NASDAQ: CLBT) currently have 208.08M outstanding shares and institutions hold larger chunk of about 38.56% of that.
The stock has a current market capitalization of $4.52B and its 3Y-monthly beta is at 1.47. It has posted earnings per share of -$1.55 in the same period. It has Quick Ratio of 1.78 while making debt-to-equity ratio of 0.04. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CLBT, volatility over the week remained 6.13% while standing at 4.23% over the month.
Analysts are in expectations that Cellebrite DI Ltd (CLBT) stock would likely to be making an EPS of 0.09 in the current quarter, while forecast for next quarter EPS is 0.1 and it is 0.5 for next year. For the current quarter EPS, analysts have given the company a lowest target 0.07 which is 0.1 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of 0.08 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 118.85% while it is estimated to increase by 26.03% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Needham on March 28, 2024 offering a Buy rating for the stock and assigned a target price range of between $13 and $13.50 to it. On February 16, 2024, BofA Securities Upgrade their recommendations, while on July 19, 2023, Craig Hallum Initiated their ratings for the stock with a price target of $11. Stock get a Mkt perform rating from William Blair on August 12, 2022.
